ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag clinical trials business tuberculosis regulation

Vitamin D on Trial
Amy Maxmen | Mar 1, 2012 | 10+ min read
Prevention trials for vitamins and supplements are notoriously difficult, but some researchers aren’t giving up on finding proof that vitamin D helps ward off disease.
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
Updated Mar 8
A healthcare worker holds up three syringes with clear medicine
To Booster or Not: Scientists and Regulators Debate
Jef Akst | Sep 16, 2021 | 7 min read
President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Regulations And Poor Communication Slow Pediatric Vaccine Development
Kathryn Brown | May 26, 1996 | 8 min read
Vaccine Development Well-intentioned immunization efforts ignore economic realities, observers contend. By all accounts, the 1990s should be a monumental decade for pediatric vaccines. Wielding new molecular tools like genetic engineering, scientists can craft safer and more creative vaccines than ever imagined. Yet poor communication and disparate desires among industry players plague the vaccine pipeline, according to insiders. As a result, they say, vaccine R&D is taking a hit, investors
DNA Probes Yield Expanded Research And Clinical Uses
Ricki Lewis | Jan 9, 1994 | 10 min read
Author: Ricki Lewis Date:January 10, 1994, pp.17 The following vendors develop and/or market DNA probes for a variety of research and diagnostic purposes. For information about specific services, products, and prices, please contact these companies directly. Lofstrand Laboratories 7961 Cessna Ave. Gaithersburg, Md. 20879 (310) 330-0111 Fax: (301) 948-9214 Microbiological Associates Inc. Life Sciences Center 9900 Blackwell R
Banking on iPSCs
Kerry Grens | Sep 1, 2014 | 5 min read
A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.
Banking on iPSCs
Kerry Grens | Jun 29, 2014 | 6 min read
A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.
The Surgisphere Scandal: What Went Wrong?
Catherine Offord | Oct 1, 2020 | 10+ min read
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.

Run a Search

ADVERTISEMENT